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ABSTRACT 
 
Mycoplasma hyopneumoniae is the causative agent of enzootic pneumonia in swine. 
Infection with M. hyopneumoniae results in a mild, chronic disease and is further 
complicated by the establishment of other secondary infections. M. hyopneumoniae has finite 
biosynthetic capabilities, including a deficit in de novo nucleotide synthesis. Recent research 
has demonstrated that neutrophils can produce extracellular traps (ETs), chromatin nets 
decorated with granular proteins released into the extracellular environment for the purpose 
of interacting and sequentially eliminating pathogens. We hypothesized that M. 
hyopneumoniae was able to utilize a membrane nuclease to obtain nucleotides from 
extracellular traps to synthesize its own DNA. The human monocytic cell line THP-1 was 
used as a model since macrophage extracellular traps (METs) are structurally similar to 
neutrophil extracellular traps (NETs). The thymidine analog ethynyl deoxyuridine (EdU) was 
used as a DNA label and was detected using a fluorescently labeled azide in a copper-
catalyzed reaction coined “Click” chemistry. Prior to beginning the MET studies, the M. 
hyopneumoniae membrane nuclease activity was validated using a DNA degradation assay. 
Then, THP-1 cells were incubated with 10 µM EdU for 24 h and induced with 200 nM 
phorbal myristate acetate for 36 h for the production of EdU-labeled METs. M. 
hyopneumoniae was incubated with these METs for 6 h followed by EdU was detected using 
an Alexa555-labeled azide, and fluorescence confocal microscopy. To test whether the 
nucleases were required for procurement of the EdU, nuclease co-factors Mg2+ and Ca2+ were 
chelated using EDTA and EGTA prior to incubating M. hyopneumoniae with the EdU-
labeled METs for 6 h and visualizing the bacterial cells for EdU transfer. The results showed 
 viii 
that when M. hyopneumoniae is incubated with EdU-labeled METs, METs are degraded and 
the EdU can be visualized co-localized within M. hyopneumoniae DNA. Additionally, when 
the nucleases are deprived of Mg2+ and Ca2+, METs remain intact and little to no EdU is 
visualized in M. hyopneumoniae DNA. The transfer of EdU from METs to M. 
hyopneumoniae DNA allows us to conclude that M. hyopneumoniae degrades host ETs likely 
via a membrane nuclease and uses the free nucleotides for its own DNA synthesis. 
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CHAPTER 1. INTRODUCTION 
General Introduction 
Mycoplasma hyopneumoniae is a swine pathogen that lacks a cell wall, has a reduced 
genome, and is considered the etiological agent of swine enzootic pneumonia (EP) (1). 
Through reductive evolution, the genome of M. hyopneumoniae is quite minimal, lacking 
main biosynthetic pathways such as purine and pyrimidine synthesis (2). Chronic EP can 
partially be attributed to the loss of cilia along the tracheal epithelium resulting in a 
nonfunctional mucociliary elevator and the introduction of secondary pathogens (3). In 2017, 
the size of the United States swine industry was estimated to be a population of 73.2 million 
head animals (4). The swine industry has continued to grow throughout the years despite 
setbacks due to Mycoplasma infections, but the economic losses have ranged well into the 
millions of dollars. Despite being a major contributor to economic losses in the swine 
industry, the mechanisms of pathogenesis carried out by M. hyopneumoniae are poorly 
understood.  
Mycoplasma hyopneumoniae infections are usually low in mortality but chronic in 
nature suggesting that this microorganism is capable of modulating the host immune system 
in order to survive and persist. Recent studies have shown the capabilities of a number of 
microorganisms to induce neutrophil extracellular traps (NETs), chromatin structures 
sprinkled with granular proteins (5). These web-like structures are utilized by the host innate 
immune system to trap and kill invading pathogens that may be resistant to phagocytosis or 
particularly difficult to eliminate. As evolution takes its course, bacteria have evolved 
mechanisms to escape these NETs resulting in persistent infections and dissemination 
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throughout the host. These mechanisms include altering the microbial cell surface to make 
them resistant to entrapment, inhibiting the release of NETs, or degrading the NETs with a 
nuclease (6). A NET-degrading nuclease has been identified in Mycoplasma pneumoniae (7), 
a human pathogen, and membrane-associated nuclease activity has been previously reported 
in M. hyopneumoniae (8, 9). Here, we report the use of a membrane-bound nuclease on the 
M. hyopneumoniae cell surface that is able to degrade extracellular traps and utilize the freed 
nucleotides for the synthesis of its own DNA. The outcomes of this study have improved our 
understanding of the pathogenesis of M. hyopneumoniae and may lead to development of 
better therapeutic agents for the control and elimination of M. hyopneumoniae infections in 
swine herds worldwide. 
Literature Review 
Mycoplasma Introduction 
Mycoplasmas are prokaryotes characterized by the lack of a cell wall (10), contain 
relatively small genomes (11, 12) and belong to the class Mollicutes, Analysis of the 16S 
ribosomal RNA reveals that Mollicutes likely arose through reductive evolution from the 
Firmicutes with a gram-positive cell wall and low G+C content (2, 11, 13). Mycoplasma 
species have been described to inhabit a variety of hosts worldwide including vertebrate 
animals, insects, and plants (11, 14) and tend to be host specific (14). The small and 
consequentially minimal genomes of mycoplasmas make these prokaryotes obligate parasites 
of their hosts; infection tends to be chronic with high morbidity but low mortality (2, 11). As 
is the pattern for most pathogenic bacteria that cause chronic infections of animals, bacteria 
must prevail through two critical stages of infection. First, the pathogen needs to establish 
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colonization of the host without being swept away by innate immune functions. Second, the 
pathogen needs to escape recognition by the immune system in order to persist in the host. 
Mycoplasmas succeed by interacting and adhering to the mucosal sites of their host including 
the surfaces of the respiratory, reproductive, and conjunctival epithelium surfaces (12). Some 
mycoplasmas, like M. pneumoniae, accomplish adhesion through specialized tip organelles, 
while some mycoplasma rely solely on membrane proteins for adhesion (15). 
 Pathogenesis 
Genome analysis among Mycoplasma species illustrates a basic genome normally 
containing mostly essential genes and lacking major biosynthetic pathways. The differing 
biochemical activities among Mycoplasma species are vast, but they are united by 
deficiencies in metabolic capabilities. Mycoplasma species lack pathways for cell wall 
production, de novo synthesis of purines and pyrimidines, and have truncated respiratory 
systems to name a few (2, 12). Probably the most notable requirement of Mycoplasma 
species is the need for fatty acids and lipids for membrane synthesis (13, 16). The close 
association of mycoplasmas with the host cell membranes may prove to be advantageous for 
the procurement of these macromolecules. In regards to membrane components, 
mycoplasmas can be categorized into sterol or sterol non-requiring mycoplasma (16). In in 
vitro broth growth, this requirement is most likely supplied by albumin from the serum 
component, a known carrier of lipids and cholesterol. Although most Mycoplasma species 
require an exogenous source of cholesterol to support the growth of the organism, a handful 
of Mycoplasma species, such as Acholeplasma laidlawii and Mycoplasma granularum, seem 
to be uninhibited by the absence of cholesterol in in vitro growth media (16).  
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Their chronic infection can be attributed to the insufficient display of pathogen-
associated molecular patterns (PAMPs) on the surface of Mycoplasma species. PAMPs are 
recognized by pattern-recognition receptors (PRRs) on innate immune cells, and the absence 
of pathogen recognition by these receptors contributes to the successful evasion of the host 
immune system (17). Unlike classical pathogens, mycoplasma cells are void of common 
immunostimulatory components such as lipoteichoic acid, lipopolysaccharide (LPS), 
peptidoglycan, or flagella. However, the cytoplasmic membrane of mycoplasmas does 
contain unique lipoproteins that could act as effective immunostimulatory components (18). 
These diacylated lipoproteins are activators of toll-like receptors TLR-2 and TLR-6 resulting 
in cytokine production from activated monocytes and macrophages (18). Like many 
pathogens, population diversity can be generated through random mutations in the 
chromosome that result in a change of phenotype. Although the protein coding capacity of 
mycoplasmas is relatively simple, mycoplasma lipoproteins can participate in a wide range of 
antigenic variation. Mechanisms like slipped-strand mispairing or recombination are most 
frequently witnessed in some Mycoplasma species due to homopolymeric stretches within 
the coding regions of lipoprotein genes (19). These polymorphisms generate genetic diversity 
among the Mycoplasma population through phase shifting and size variation. This ensures 
that at least a subset of the population will continue to persist in the host even if a portion of 
the population is recognized by the host immune defenses.  
A number of Mycoplasma species, including M. hyopneumoniae (20), have the 
capabilities to produce a capsule, which can participate in antigen mimicry to evade the host 
immune system (21). The capsule and the antigenic variation within the capsular 
polysaccharides can have a major impact on the survival of a bacterium in a particular niche. 
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The polysaccharide shell is attributed to many bacterial protections including 
antiphagocytosis, adhesion, biofilm formation, and circumvention of the immune system (14, 
21). In the case of Mycoplasma, it is also speculated that the capsule plays a role in antigen 
mimicry due to the absorption of host materials for the construction of the capsule, thus 
further aiding in evasion of the immune system (21).  
Mycoplasma hyopneumoniae 
Mycoplasma hyopneumoniae is the etiological agent of enzootic pneumonia (EP) and 
major contributor of porcine respiratory disease complex (PRDC) in swine (1, 20, 22, 23). 
Infection with M. hyopneumoniae is host specific and is present in pigs worldwide. A 
genomic study on M. hyopneumoniae strain 232 completed by Minion et al. in 2004 revealed 
a number of unique genomic features including a rich A + T content (~70%), genes with 
tandem repeats to enable phase switching or size variation, two paralog gene families (P97 
and P102), and high protein coding capacities due to the minimal genome (24). The 
mechanisms in which M. hyopneumoniae avoids the host immune response and establishes a 
persistent infection is unclear. Like other Mycoplasma spp., M. hyopneumoniae lacks major 
biosynthetic pathways, including those for purine and pyrimidine synthesis, although they do 
contain salvage pathways (2). Additionally, ABC transporters can be readily identified (8, 
24), which are necessary considering the dependence of M. hyopneumnoiae on its host for 
major macromolecule precursors. Virulence factors within the genome, other than adhesin 
proteins of the P97 and P102 gene families, have not been identified (24). However, the 
virulence mechanisms of M. hyopneumoniae are impactful, allowing for the establishment of 
secondary infections within the host.  
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M. hyopneumoniae is highly infectious and can be transmitted between pigs via direct 
contact with respiratory secretions or through the air (1). Enzootic pneumonia is 
characterized by a nonproductive cough, lung lesions, and poor growth and feed conversion 
(20, 23). The lung lesions are due to the response of the host immune system and the 
cytotoxic activities of phagocytic cells involved in the chronic immune response (25). 
Typically, respiratory pathogens can be cleared with the help of the innate immune system 
via the mucociliary elevator. This system clears the bronchi of pathogens or other particulate 
matter from the air by trapping it in mucus that lines the respiratory epithelium. Within this 
mucus are hair-like structures called cilia that beat and help to move the mucus up the 
respiratory tract to eventually be swallowed or expelled from the body by coughing. The 
nonproductive cough is the result of deciliation caused by the adherence and colonization of 
M. hyopneumoniae on the mucosal surfaces of the trachea, bronchi, and bronchioles (26). 
Adherence is mediated primarily by the adhesin protein P97, a protein attributed to the 
successful colonization and persistent infection in swine (27, 28). Additional virulence 
factors of M. hyopneumoniae include a polysaccharide capsule (20), antigenic variation in 
membrane lipoproteins, methylases, and nucleases (29). The rate of secondary infections in 
pigs harboring M. hyopneumoniae and the increased severity of disease from these secondary 
infections suggests that the immune system of the pig is modulated in some negative way. 
How this might occur is poorly understood. The significant impact of M. hyopneumoniae on 
the swine industry in combination with the lack of effective control measures against the 
infection calls for more research in order to increase our understanding of the organism’s 
virulence mechanisms.  
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 Pigs harboring M. hyopneumoniae are more susceptible to other respiratory diseases 
like the porcine respiratory disease complex (PRDC) and the porcine reproductive and 
respiratory syndrome virus (PRRSV) (22, 29, 30). Mycoplasma hyopneumoniae rarely results 
in mortality but the resulting slow growth of the pig and cost of treatment proves to be an 
economic issue. Infection with M. hyopneumoniae directly and indirectly results in major 
economic losses for the swine industry, estimated to be roughly $4.99 per pig in 2015 (31). 
Current prevention and treatment methods for the control and eradication of M. 
hyopneumoniae infections have poor performance. Due to the lack of a cell wall, M. 
hyopneumoniae is intrinsically resistant to antimicrobials that target cell wall production, like 
the beta-lactam class of antibiotics. Current vaccines utilize an inactivated, whole-cell 
preparation containing an adjuvant, but the resulting immune response is still tenuous making 
protection minimal (29). The current best practices include herd closure for eliminating an 
infection within a herd and careful screening of incoming pigs (32). Thus more research is 
needed to provide insight into potential vaccine targets and other therapeutic agents for 
successful elimination of M. hyopneumoniae among swine herds worldwide. 
Extracellular Traps (ETs) 
 Immunological importance 
Two major lines of defense protect the body: the innate immune system and the 
adaptive immune system. The innate immune system contributes to nonspecific protection 
and is composed of physical barriers (e.g., skin, mucosal surfaces), soluble antimicrobial 
molecules (e.g., complement system, defensins, cytokines), and cellular responses from 
phagocytic leukocytes and other nonspecific-acting cell types (33). Of the four phagocytic 
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white blood cells, neutrophils are one of the most active and mobile cells against bacterial 
infections, dependently arriving first to the site of infection by chemotaxis (33). When in 
contact with an invading pathogen, receptors on the neutrophil cell surface become activated 
resulting in the binding and ingestion of the microorganism and entrapping it in a phagosome 
(34). This mechanism is defined as phagocytosis and is key in dismantling attacks by 
invading pathogens. Once the pathogen is inside the phagosome, the vacuole fuses with a 
granule inside the neutrophil, which contain an arsenal of weapons including enzymes, 
antimicrobial peptides, and reactive oxygen species (ROS) that can decimate the captured 
pathogen(s) (34, 35). The contents of these granules can also be released from the neutrophil 
into the extracellular environment in a second defensive mechanism called degranulation. 
Until recently, phagocytosis and degranulation were assumed to be the primary mechanisms 
used by neutrophils to contain and directly kill invading microorganisms. However, in 2004, 
Brinkmann et al. announced a third mechanism of pathogen elimination by the release of 
neutrophil extracellular traps (NETs) into the environment (5). These web-like structures are 
composed of decondensed chromatin that is sprinkled with granular proteins.  
In a little over a decade, NETs have become an impactful discovery with their release 
having profound ramifications on eliminating invading pathogens. Thus far, in vitro studies 
have demonstrated that NETs play a role in immobilizing pathogens, inhibiting their growth, 
and/or killing these invading microorganisms. The potential for the extracellular, 
decondensed chromatin to expand upon release allows NETs to defend against large 
pathogens like hyphal fungi that otherwise would not be able to be phagocytized (36-38). 
Although the release of NETs can be triggered by a number of microorganisms, NETs pose 
as a double-edged sword in that they play a dynamic role as effector cells, but may have great 
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potential to inflict tissue damage on the host resulting is disease. The lifespan of a neutrophil 
is highly regulated to inhibit the accidental release of its cytotoxic contents like ROS, causing 
damage to the surrounding host tissues. However, the release of NETs automatically 
introduces these cytotoxic chemicals as well as proinflammatory signals (e.g., cell-free DNA) 
into the environment. Ongoing research has provided an overwhelming amount of evidence 
on the negative relationship between NETs and autoimmune disorders with resulting 
undesired pathology in the host upon release of the extracellular traps (35, 39-41).  
NETs occur when the neutrophil undergoes several morphological changes and 
releases its chromatin and cell associated proteins into the surrounding environment where it 
can interact with pathogens. In general, the pathogen can become entangled in this web-like 
structure and be exposed to proteases, antimicrobial peptides, and ROS originating from the 
neutrophil granules. Although many of the puzzle pieces involved in understanding NETs 
relating to their formation and composition are yet to be found, it is well established that 
NETs can play an integral role in containing and eliminating a variety of infections.  
 Formation of Extracellular Traps 
The immune system encounters a wide array of invading microorganisms daily. The 
diversity of these microorganisms challenges the innate immune system to be prepared on 
every possible front, which is why we see an extensive variety of defense mechanisms with 
NETosis being one of several. Within NETosis, though, there are variations in the 
composition and release of NETs that are currently being studied. These variations include 
suicidal NETosis that leads to neutrophil cell death, vital NETosis characterized by a lack of 
plasma membrane rupture, and a third type of NETosis that releases mitochondrial DNA 
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(mtDNA) verses nuclear DNA released in suicidal and vital NETosis (35, 41). It should be 
noted that the detailed molecular processes distinguishing these three types of NETosis and 
the timing of their release are not fully understood. The general event of NET formation can 
be divided into two main categories: ROS-dependent formation and ROS-independent 
formation. 
In ROS-dependent NET formation, ROS are produced by NADPH oxidase (NOX) 
upon neutrophil stimulation resulting in suicidal NETosis (42). When the receptors of a 
neutrophil are activated by a stimulant, the endoplasmic reticulum (ER) releases calcium ions 
(Ca2+) into the cytoplasm. The increase of calcium in the cytoplasm triggers an important 
series of signal transduction events beginning with an upregulation of protein kinase C 
(PKC) activity (41). PKC is responsible for the phosphorylation of NOX2 (previously named 
gp91phox), which induces the assembly of NADPH oxidase complexes in cytoplasmic and 
phagosomal membranes (43). NADPH oxidases are responsible for transferring electrons 
from NADPH to O2 resulting in the free radical form superoxide (O2 −), a precursor of ROS. 
The presence of ROS destabilizes neutrophil internal membranes allowing proteins to diffuse 
into the cytoplasm. The diffusion of neutrophil elastase (NE), myeloperoxidase (MPO), and 
peptidylarginine deiminase 4 (PAD4) into the cytoplasm from the granules and their 
translocation into the nucleus is essential to NET formation. NE cleaves histones and PAD4 
participates in post-translational modifications of histones by hypercitrullination, both 
mediating the transition of chromatin from a condensed to a decondensed state (35, 44). The 
functionality of PAD4 is reliant on calcium cofactors, making the increase of calcium ions 
due to ROS an important step in driving NETosis. Although MPO has peroxidase 
capabilities, MPO does not seem to be directly involved in the decondensation on chromatin, 
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however, it there is evidence that the protein enhances the activity in NE resulting in more 
effective chromatin decondensation (45). The abundance of ROS promotes the loss of the 
nuclear membrane and the nuclear, cytoplasmic, and granular contents mix followed by the 
subsequent extrusion of DNA and associated proteins through membrane pores and eventual 
cell lysis. A subset of NET formation that is ROS-dependent includes the quick release of 
mitochondrial DNA and is driven by ROS produced by the mitochondria instead of NADPH 
oxidase-derived ROS (46, 47). This method avoids instant cell death as seen in the release of 
nuclear DNA, but little is known regarding the signaling processes resulting in the release of 
mitochondrial DNA over nuclear DNA.  
NET formation independent of ROS is still somewhat controversial but is 
characterized by a functional anuclear cytoplast and is the primary pathway for vital 
NETosis. This pathway can induce a rapid release of nuclear DNA in contrast to the ROS-
dependent pathway, which can require multiple hours before the extrusion of NETs. Vital 
NETosis has been stimulated primarily by ligand binding to TLRs and binding of C3 to 
complement receptors or by platelet activation (35, 48). In this pathway, the chromatin still 
decondenses, but in contrast to ROS-dependent NET formation, the nuclear contents are 
trafficked to the cytoplasmic membrane and released into the environment without the 
disintegration of the nuclear membrane. This process occurs independent of ROS production 
(35). By maintaining the integrity of the plasma membrane, the anuclear cytoplasts are still 
able to function in phagocytosis and chemotaxis, hence the name vital NETosis (49, 50).  
It is worth mentioning that many critics find it difficult to believe NETosis to be a 
controlled host-mediated defense mechanism. Neutrophil recycling homeostasis is highly 
regulated to protect host tissues from being injured by the cytotoxic granule contents, so the 
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fact that there are an abundance of stimuli reported to produce NETs is controversial. In 
addition, the role NETs play in aggravating autoimmune diseases and the inadvertent 
activation of NETosis also rule against NETosis being a highly regulated host mechanism 
and point more towards a happenstance event. Regardless, a large portion of in vitro research 
advocates for NETs as an integral part of fighting off invading pathogens.  
 Structure of Extracellular Traps 
NETs are composed primarily of double stranded DNA (dsDNA) sprinkled with 
proteins and peptides derived from granules, the nucleus, and the cytoplasm (51). The 
decondensed chromatin from the lobular nucleus of the neutrophil is extruded from the 
neutrophil and expands into the extracellular environment. This creates a sizeable web-like 
structure for the ensnarement of invading pathogens, and it also provides a localized 
environment for antimicrobial agents from the neutrophil to reside in high concentrations for 
effective elimination of pathogens (51). The negative charge of DNA is fundamental to the 
effectiveness of NETs because it intrinsically attracts these cationic antimicrobial factors and 
concentrates them in one location to act as an arsenal of weapons against pathogens, but 
DNA’s anionic character also protects the host from off-targeted and detrimental injury to 
surrounding tissues. These antimicrobial factors are derived from three locations within the 
neutrophil: the nucleus, granules, and the cytoplasm. 
The nucleus of a eukaryotic cell houses chromatin, which is composed of DNA 
organized around histones. For a period of time, the role of DNA in NETs was thought to act 
primarily as a scaffold for the delivery of antimicrobial materials to the invading pathogens. 
However, the anionic charge of DNA plays an active role in electrochemical interactions 
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with pathogens (52). These interactions aid in the entrapment of microorganisms and prove 
that the DNA scaffold is not simply a passive structure. Histones are cationic proteins that 
provide structural support and organization within the nucleus and also aid in regulating gene 
expression. These proteins that constitute a large portion of the protein content in chromatin 
have been shown to exhibit antimicrobial properties through the formation of antimicrobial 
peptides (AMPs) by proteolytic cleavage of histones by neutrophil elastase (53). AMPs, 
particularly peptides generated from histone protein H2A, act as cationic defensins in the 
innate immune system by harnessing their cationic charge and amphipathic nature to insert 
themselves into the membranes of pathogens causing the lysis of the microorganism (39, 53, 
54). AMPs can also function by inhibiting intracellular functions such as nucleic acid 
synthesis or other enzymatic activities (54). Since histones are found in chromatin, which is 
released in the process of NETosis, the abundance of histones found in extracellular traps far 
out numbers any other protein from the cytoplasm or neutrophil granule found in NETs (37). 
This makes histones and the subsequent derivation of AMPs critical in the effectiveness of 
NETs. 
When a neutrophil phagocytizes a microbe, it readily fuses the microbe-containing 
phagosome with the internal granule. Granules contain enzymes, peptides, and ROS. In the 
process of NETosis, the granule and nuclear membranes break down and the contents of the 
cell are released, bathing NETs with granular contents through cationic (protein) – anionic 
(DNA) interactions (51). The azurophilic, or primary, granules of neutrophils contain the 
majority of hydrolytic enzymes and bactericidal proteins found in NETs such as neutrophil 
elastase (NE), cathepsin G, and myeloperoxidase (MPO) (37, 55). These proteases and 
peroxidase, respectively, are major bactericidal agents among some of the lesser proteins 
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found among NETs including lactoferrin, bactericidal permeability-increasing protein (BPI), 
catalases, lysozyme C, and defensins. The majority of these agents act to kill pathogens by 
targeting bacterial membranes or components of the membrane, particularly NE that has the 
capabilities to cleave virulence proteins secreted by pathogens or that are located on the 
pathogen’s outer membrane (56). In addition to enzymatic activities, proteins located in 
NETs can serve as chelator agents, sequestering nutrients often competed for by microbes. 
For example, lactoferrin chelates iron, an essential element required by bacteria for growth, 
and by doing so, it restricts bacterial replication and aids the host in containing infections.  
Cytoplasmic proteins are not well represented in NETs, which is peculiar given that 
the entire contents of the cell mix prior to the expulsion of the extracellular traps from the 
neutrophil upon eventual lysis of the terminally differentiated white blood cell. Calprotectin 
is one of the only cytoplasmic proteins identified in NETs, and it is thought to be essential in 
combating fungal infections (37). Since fungi and their hyphae are too large to be 
phagocytized by neutrophils, NETs are required to sequester pathogens and prevent 
dissemination of the pathogen throughout the host. Calprotectin works as a chelating agent 
for Ca2+, Mn2+, and Zn2+, which are required for fungal growth (37). By sequestering these 
metal ions, fungal growth is no longer supported thus eliminating the spread of the fungal 
infection and allowing time for the rest of the antifungal agents in the NETs to work at 
clearing the fungal infection. Calprotectin’s chelating properties must also be beneficial in 
binding ions required for bacterial growth thus resulting in slowed growth of microbial 
pathogens. 
The structure of NETs presents itself as this random web of DNA and proteins loaded 
with an arsenal of weapons against pathogens, but further study shows that the composition 
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of NETs is strategic and must have been carefully selected over time to include an effective 
mixture of antimicrobial agents. The effectiveness of these extracellular traps against a 
variety of microorganisms (i.e., bacteria, fungi, viruses, and parasites) proves their invaluable 
role as a member of the innate immune system. 
 Bacterial resistance mechanisms 
The interaction between bacteria and eukaryotic hosts has been established for 
centuries, both competing in a never-ending arms race, constantly rushing to outcompete the 
other for survival. The Red Queen hypothesis summarizes this relationship by explaining 
how organisms are constantly evolving to survive the pressures from other organisms and 
environments (57). In the case of bacteria and extracellular traps (ETs), the host evolved 
ways to combat invading pathogens, and the invading pathogens have evolved resistance 
mechanisms in response. There are currently three main strategies used by bacterial 
pathogens to counteract the killing nature of ETs: inhibiting ET release, degrading ETs, and 
resisting ET entrapment. Several studies have demonstrated that pathogens often use a 
combination of these mechanisms to ensure their survival and dissemination in the host. 
As discussed previously in the formation of extracellular traps, there are several 
triggers required for the release of these structures from white blood cells. Many of those 
triggers are still not completely understood, however the production of ROS is consistent 
with successful ETosis. Interference with ROS production is a strategy utilized by group A 
Streptococcus pyogenes (GAS), an upper respiratory tract pathogen (58). This pathogen 
inhibits the phosphorylation of the extracellular signal-regulated kinase (ERK) cascade, 
which signals NADPH oxidase to produce ROS (58). GAS also induces the production of IL-
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10 by the neutrophil (58). Unrelated to ROS production, there is evidence in the case of 
Strepetococcus suis serotype 2, a swine pathogen, that the production of biofilms can inhibit 
the release of NETs altogether (59). The molecular basis of this finding has been observed in 
vitro but has not yet been characterized in vivo. 
All of these strategies result in the suppression of NETosis thereby inhibiting the 
release of NETs and aiding Streptococcus infections of the upper respiratory tract and 
onwards throughout the host. In addition, GAS, as well as other pathogens, thwarts 
extracellular traps by degrading the extracellular DNA structure. 
Many NET-degrading strategies by pathogens have been focused on the pathogen’s 
production of nucleases that are used to degrade the DNA structures. S. pneumoniae, 
Staphylococcus aureus, M. pneumoniae and other upper respiratory tract pathogens have 
exhibited nuclease activity in which there is a higher rate of bacterial survival when the 
nucleases are employed (7, 58). The complete extent of nuclease utilization by these 
pathogens is not greatly understood, however, the nuclease proves to be beneficial in 
deconstructing an immune defense mounted against the pathogens, aiding in their survival. 
Interestingly, current investigators are looking into the host’s defense response to pathogen 
nuclease activity and are looking at cathelicidin found in NETs as a protective agent against 
extracellular trap degradation (40). No other degradation strategies of extracellular traps have 
been discovered, but bacteria can still render the traps ineffective by modifying their cell 
surfaces instead of modifying the extracellular traps directly. 
Microorganisms are known to undergo phase variation, a method of surviving 
environments where the conditions change rapidly. Different types of phase variation include 
the expression of pili, flagella, toxin production, antigenic variation, biofilm formation, and 
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capsule production to name a few. In terms of evading ETs, one of the most effective 
mechanisms employed by bacteria is the modification of its cell surface via antigenic 
variation, production of a capsule, or production of a biofilm. These approaches used by 
bacteria facing entrapment by extracellular DNA aid the pathogen by masking the negative 
charge on the membrane surface to evade electrostatic interactions with NET components 
(60).  
The coevolution of extracellular traps and resistance mechanisms by pathogens is a 
never-ending race that continues to evolve today. Thankfully, not all pathogens have the 
capabilities to utilize one or all of these mechanisms. Studying these resistance mechanisms 
provides insights into resistance mechanisms by pathogens that cause persistent infections 
and can possibly aid in providing tools, like pharmaceuticals, against these mechanisms, to 
eliminate these chronic and persistent infections. 
 Mycoplasma interaction with NETs 
Mycoplasma pneumoniae, a human pathogen, is able to evade NET-mediated killing 
by degrading extracellular traps via a secreted nuclease (7). The conditional release of NETs 
and their direct role in the innate immune system is still to be fully understood, but several 
studies indicate that NETs are seen in infections with pathogens that are either too large to be 
phagocytized (i.e., fungal hyphae, bacterial aggregates) or evade phagocytosis entirely (61). 
Interestingly, numerous mycoplasmas exhibit survival mechanisms that allow them to resist 
neutrophil phagocytosis (62), including M. pneumoniae (7). A study by Yamamoto et al. 
reported that M. pneumoniae could both induce NETs and degrade them with the secreted 
nuclease Mpn491 (7). The degradation of the extracellular traps could be a possible reason 
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for the modulation of the host immune system by mycoplasmas and the common 
establishment of secondary infections.  
 Hypothesis  
The presence of membrane bound nucleases on the surface of M. hyopneumoniae and 
an essential need for host-derived purines and pyrimidines, along with the ability of M. 
hyopneumoniae to evade host and cause a persistent infection leads us to hypothesize that M. 
hyopneumoniae can dismantle ETs and utilize the free nucleotides for the construction of its 
own DNA. To test this hypothesis, we have chosen to use the human monocytic cell line 
THP-1, which was previously shown to produce ETs when stimulated appropriately, as an ex 
vivo model to study the interactions of M. hyopneumoniae with extracellular traps.   
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CHAPTER 2: MATERIALS AND METHODS 
 
Bacterial Strains and Cultures 
Mycoplasma hyopneumoniae strain 232 is a derivative of strain 11, a commonly used 
strain in the United States to study virulence (24). It was cultured in a modified Friis medium 
containing 20% heat-inactivated (55°C, 30 min) porcine serum (Gibco, Life Technologies) 
and fresh yeast extract, supplemented with Cefobid (25 µg/mL) (63). The liquid cultures 
were grown at 37°C in a rotating incubator. The human monocytic cell line THP-1 (ATCC® 
T1B-202™) was cultured in RPMI-1640 (GE Healthcare Life Sciences) supplemented with 
10% heat-inactivated, fetal bovine serum (Atlanta Biologics). The cultures were maintained 
at 37°C with 5% CO2 and were subcultured every 3-5 days.  
DNA Labeling 
Cy3-dNTP Labeling of PCR-amplified DNA 
Deoxynucleotide triphosphates (dNTPs) with Cy3 fluorescent labels (Perkin Elmer) 
were tested for the ability of DNA polymerase to incorporate them into DNA. A PCR 
product was generated using Taq DNA polymerase (Invitrogen) and a mixture of Cy3-dNTPs 
and non-fluorescent dNTPs (Fermentas). A stock solution of dNTPs was made by mixing the 
following: 10 mM dTTP, 10 mM dGTP, 10 mM dCTP, 10 mM dATP, and 1 mM Cy3-dATP. 
The final concentration of each dNTP in the final PCR reaction was 200 µM. Amplification 
of the template DNA was confirmed using agarose gel electrophoresis. A FLUOstar Omega 
microplate reader (BMG Labtech) was used to detect fluorescence of the PCR product using 
excitation and emission wavelengths of 544 nm and 590 nm, respectively.  
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Labeling THP-1 Cells and M. hyopneumoniae DNA with Cy3-dNTPs 
THP-1 cells grown in suspension were incubated with one to three different Cy3-
labeled dNTPs. The ratios of labeled to unlabeled analogs were varied and incubation was 
carried out for 24-48 h. Mycoplasma hyopneumoniae cultures were treated in a similar 
fashion. Both THP-1 cells and mycoplasmas were then visualized by fluorescence confocal 
microscopy. 
Bromodeoxyuridine (BrdU) Labeling of PCR-amplified DNA 
BrdU is a thymidine analog and was tested for its incorporation into DNA by PCR. Its 
advantage is the specific antibody-based detection system that theoretically could allow the 
transfer of labeled nucleotides to the mycoplasma. First, a dNTP stock was made containing 
200 µM dGTP, dATP, and dCTP, 150 µM dTTP, and 50 µM BrdU (eBioscience). The dNTP 
stock was used to amplify a 2.8 Kb PCR product using Taq polymerase (Invitrogen). 
Amplification of the DNA was determined by running the PCR product on a 0.7% agarose 
gel with post staining in ethidium bromide. When the PCR product was confirmed, a dot blot 
was used to assess the presence of BrdU. Because of the need for antibody detection of 
BrdU, the PCR products needed to be denatured prior to being blotted on the nitrocellulose 
membrane to allow antibody recognition of the incorporated BrdU. PCR products were 
denatured in 0.4 M sodium hydroxide and 10 mM EDTA and heated to 98 °C for 10 min. 
The solution was neutralized with an equal volume of cold 2 M ammonium acetate. The 
denatured PCR products were then blotted on the nitrocellulose membrane in 5 µl aliquots, 
allowing the previous aliquot to dry before applying the next aliquot. Soluble BrdU was also 
added to the membrane as a control. The membrane was blocked in 1% fish skin gelatin 
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(Sigma) overnight at 4 °C with agitation. The membrane was then washed with Tris buffered 
saline- Tween 20® (VWR) (TBST) for 5 min, three times. After washing, a 1:1000 dilution of 
anti-BrdU, mouse monoclonal antibody (Clone MoBU-1) Alexa Fluor-555 (Invitrogen Life 
Technologies) in TBST was incubated with the membrane for 1 h at room temperature with 
shaking. The membrane was washed again with TBST prior to adding the alkaline 
phosphatase conjugated goat anti-mouse IgG, IgM (H + 2) cross-absorbed secondary 
antibody (Invitrogen). The secondary antibody was diluted 1:1000 in TBST and incubated 
with the membrane for 1 h at room temperature with shaking. The membrane was washed for 
a final time prior to adding SIGMAFAST™ Fast Red TR/Naphthol AS-MX substrate 
(Sigma-Aldrich). The substrate and membrane were incubated until noticeable detection of 
BrdU was seen.  
Labeling THP-1 Cells and M. hyopneumoniae DNA with Bromodeoxyuridine  
To label THP-1 cells and M. hyopneumoniae with BrdU, a modified eBioscience 
protocol was used. THP-1 cells were incubated with 10 µM BrdU in RPMI-1640 
supplemented with 10% FBS at 37°C with 5% CO2 for 24 h. The THP-1 cells were prepared 
per manufacturer’s instructions. Briefly, the THP-1 cells were incubated in the 1X BrdU 
Staining Buffer (provided) for 15 min at room temperature in the dark. Next, cells were 
washed and resuspended in DNase I solution (eBioscience) for 1 h at 37°C in the dark. 
DNase I was added to provide the anti-BrdU antibody with access to incorporated BrdU. 
Finally, an Alexa555-conjugated anti-BrdU antibody (Invitrogen Life Technologies) was 
incubated with the cells (1:1000). The cells were gently washed and were viewed via 
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confocal microscopy. Mycoplasma hyopneumoniae was treated in a similar way except the 
cells were labeled in Friis media without CO2 
Labeling THP-1 Cells and M. hyopneumoniae DNA with 5-Ethynyl-2’-Deoxyuridine 
(EdU) 
The Click-iTTM Plus EdU Alexa FluorTM 555 Imaging kit (Life Technologies) was 
used throughout these studies. THP-1 monocytes were incubated with 10 µM EdU (Life 
Technologies) for 24 h at 37°C with 5% CO2. Length of incubation time was based on the 
replication rate of THP-1 cells. After incubation, the labeled cells were spun down and the 
EdU-containing supernatant was aspirated. The labeled THP-1 cells were washed three times 
in 5 mL of RPMI-1640 at 1000 x g for 5 min. The samples were prepared for microscopy as 
described below. 
Mycoplasma hyopneumoniae was grown to mid-log phase according to the pH 
indicator prior to adding 10 µM EdU to the culture. The cells were incubated with the 
nucleotide label at 37°C with rotation for 24 h. After incubation, the cells were centrifuged at 
10,000 x g for 1 min, washed three times with 1 mL PBS and prepared for microscopy as 
described below. 
Macrophage Extracellular Trap (MET) Generation and Assay Development 
Differentiation of THP-1 Cells and the Production of METs Using PMA  
The human monocytic leukemia cell line THP-1 was used as a source for the 
production of extracellular traps since neutrophils cannot be continually maintained in 
culture. The process of inducing extracellular traps by THP-1 cells was optimized by varying 
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phorbol 12-myristate 13-acetate (PMA) concentrations, percentage of fetal bovine serum 
(FBS), and length of incubation time. The optimized conditions were as follows. THP-1 cells 
were grown in suspension, pelleted, and resuspended in RPMI-1640 with 1% FBS. EdU-
labeled and unlabeled cells were induced by adding PMA to a final concentration of 200 nM. 
The cells were then seeded at 5x105 cells/well onto sterile 12 mm glass coverslips #1 type 
(VWR) coated with sterile collagen type II from rat tail (Sigma) diluted in PBS (1:10). Prior 
to seeding, the collagen and glass coverslips were incubated in a 24-well plate at 37°C in 5% 
CO2 overnight. After incubation, the collagen was aspirated off the coverslips and the 
coverslips were allowed to dry prior to seeding the THP-1 cells. The THP-1 cells with PMA 
were incubated at 37°C with 5% CO2 for 36 h to allow the monocytes to differentiate into 
macrophages, attach, and produce extracellular traps. After 36 h, the cells were prepared for 
microscopy as described below.  
M. hyopneumoniae Nuclease Function Assay 
The activity of the M. hyopneumoniae membrane nuclease was validated as 
previously described (9). Mycoplasma hyopneumoniae strain 232 cultures were grown to 
mid-log phase, centrifuged at 10,000 x g for 1 min, and resuspended in PBS or culture media 
at 100 µg/mL mycoplasma protein. The mycoplasma protein concentration was determined 
using a Qubit® Fluorometer 2.0 (Invitrogen Life Technologies) and the Qubit® Protein Assay 
Kit (Invitrogen Life Technologies). Each reaction containing 100 µg/mL M. hyopneumoniae 
protein also contained 1% dextrose, 5 mM MgCl2 for nuclease stimulation, and a 4 Kb PCR 
product to be degraded by the M. hyopneumoniae nuclease. The reactions were incubated at 
37°C for 30 min, and the degradation of the PCR product was confirmed on a 0.7% Tris-
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borate-EDTA (TBE) agarose gel run at 100 V for 50 min. The gel was post stained in 
ethidium bromide. This experiment was also repeated without mycoplasma in various media 
including PBS, RPMI-1640, RPMI-1640 supplemented with 10% heat-inactivated FBS and 
Friis media to exclude unintentional sources of nuclease activity.  
Assessment of PMA Activity on M. hyopneumoniae Nuclease Function  
Mycoplasma hyopneumoniae 232 was grown to mid-late log phase and diluted into 
Friis medium at 100 µg/mL protein containing PMA at a final concentration of 200 nM and 5 
mM MgCl2. A control reaction consisting of Friis medium and a 2 Kb PCR product was used 
to control for possible nuclease activity in the media. All reactions were incubated at 37°C 
and samples were taken at 30 min, 2, 4, and 24 h to assess nuclease activity. Thirty minutes 
prior to halting each reaction, the 2 Kb PCR product was added. Samples were analyzed on a 
0.7% TBE agarose gel run at 100V for 50 min, and the gel was post stained in ethidium 
bromide.  
MET Degradation by M. hyopneumoniae and Visualization 
EdU-labeled and non-labeled THP-1 cells were differentiated as described above for 
the production of METs. After incubation of the THP-1 cells with 10 µM EdU, the THP-1 
cells were pelleted and the supernatant containing unincorporated EdU was set aside for 
incubation with M. hyopneumoniae to demonstrate that it could label mycoplasma DNA. The 
labeled cells were washed three times with RPMI-1640. The supernatant of the last wash was 
reserved for incubation with M. hyopneumoniae as a control to demonstrate the removal of 
free EdU from the THP-1 culture prior to inducing extracellular traps. This was to ensure the 
THP-1 METs as the only detectable source of EdU for M. hyopneumoniae uptake and 
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labeling. After 36 h of differentiation of the THP-1 cells with PMA, an equal volume of M. 
hyopneumoniae grown to mid-log phase, was added to each well. MgCl2 was added to a final 
concentration of 5 mM to ensure to activate M. hyopneumoniae nuclease function. The 
differentiated THP-1 cells and M. hyopneumoniae mixture was incubated for 6 h at which 
time the media containing M. hyopneumoniae was aspirated and centrifuged at 10,000 x g for 
1 min to pellet the mycoplasmas. Both M. hyopneumoniae and THP-1 MET coverslips were 
prepared for microscopy as described below. 
M. hyopneumoniae Nuclease Inhibition Assay 
A M. hyopneumoniae membrane nuclease deficient mutant does not exist at this time. 
However, chelators ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic 
acid (EGTA) could be used to chelate Mg2+ and Ca2+, cofactors required for nuclease 
function (9). To test M. hyopneumoniae nuclease inhibition, the nuclease function assay as 
previously described was repeated with the addition of EDTA and EGTA in RPMI-1640 
media containing 1% FBS. EDTA, EGTA, and the combination of both EDTA and EGTA 
were added to RPMI-1640 at final concentrations of 6 mM each. PCR-generated DNA 
fragments of 1 Kb and 1.3 Kb in size were added to the reaction followed by M. 
hyopneumoniae culture prepared as previously described. A RPMI-1640 plus DNA control 
was used as a negative control to show the lack of nuclease activity in the FBS, and a 
positive control lacking EDTA and EGTA was also prepared. The reactions were incubated 
at 37°C for 30 min. A portion of the digestion was run on a 0.7% Tris-borate-EDTA agarose 
gel and post stained in ethidium bromide prior to imaging. 
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Inactivating M. hyopneumoniae nucleases in the presence of EdU-labeled METs was 
performed in a similar manner. EdU labeling of THP-1 cells and induction of MET 
production was performed as previously described. Prior to incubating M. hyopneumoniae 
with the MET structures, EDTA and EGTA were added to the MET-containing wells at final 
concentrations of 6 mM to chelate Mg2+ and Ca2+ ions. After the addition of EDTA and 
EGTA to the media, M. hyopneumoniae was added to the wells as previously described and 
incubated for 6 h. The transfer of the EdU label from the METs to M. hyopneumoniae was 
assessed by detecting EdU with an Alexa555-azide followed by fluorescent confocal 
microscopy. Preparation of the cells and microscopy details can be found below. 
Microscopy 
THP-1 monocytes and M. hyopneumoniae were prepared for microscopy in the 
following manner. All cells were fixed in 4% PFA at room temperature for 20 min followed 
by centrifugation at 800 x g for 5 min and washing with 1 mL of PBS (pH 7.4). The cells 
were then permeabilized with 0.01% Triton® X-100 (Sigma) at room temperature for 30 min. 
The cells were then washed once with 1 mL PBS. If the cells were previously labeled with 
EdU, the Alexa555-labeled picolyl azide cocktail was added according to the protocol 
provided by Life Technologies. The reaction was incubated with the cells for 30 min at room 
temperature in the dark followed by washing with 1 mL PBS. All cells were resuspended in 
ProLong Gold Antifade Reagent with DAPI (Invitrogen) and mounted onto glass slides and 
stored in the dark until imaged.  
Differentiated THP-1 macrophages induced with PMA for the production of METs 
were prepared for microscopy in the following manner. To maintain the integrity of the MET 
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structures, washes with PBS between reagents were kept to a minimum. After incubation 
with PMA, the culture media was aspirated and 1 mL of PBS was gently added to the well by 
using the side of the well as a guide for PBS delivery. PBS was incubated with the MET-
containing coverslips for 1 min before careful aspiration of the wash solution. The coverslips 
were then fixed in 4% PFA for 30 min at room temperature followed by a single wash with 
PBS for 1 min. If THP-1 METs included EdU, the Alexa555-labeled picolyl azide was added 
to the coverslips according to the protocol provided by Life Technologies for 30 min at room 
temperature in the dark. The cocktail was carefully aspirated and the cells were washed once 
with PBS prior to mounting the coverslips using ProLong Gold Antifade Reagent with DAPI 
for microscopy. The slides were kept in the dark until imaged. 
A laser-scanning confocal microscope (Olympus IX-71) using the Fluoview 2000 
software (v2.0) was used to visualize all MET structures and cells. The microscope is 
equipped with 405 nm, 488 nm, 559 nm, and 635 nm lasers, spectral photomultiplier 
detection, and a piezo stage controlling system. Laser power and exposure was kept constant 
over all experiments in which mean fluorescent intensity (MFI) was measured. Image stacks 
were collected simultaneously for nucleic acids (DAPI filter) and EdU (TRITC filter). 
Data Analysis 
Image analysis was performed using Fiji (v1.0, NIH), a derivative of Open Source 
software ImageJ (64). MFI values of EdU-labeled M. hyopneumoniae were calculated using 
Fiji by outlining each cell and measuring the mean fluorescence. The values were corrected 
to obtain the corrected total cellular fluorescence (CTCF) by measuring background readings 
and subtracting the mean background intensity from the integrated density of each cell. 
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Statistical significance of MFIs was determined by performing a Welch’s t-test with 
GraphPad software (Prism 7.0d). p-values <0.05 were considered statistically significant. 
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CHAPTER 3. RESULTS 
 
Incorporation of Nucleotide Labels in PCR Products 
Prior to utilizing Cy3-dNTPs and BrdU to label THP-1 cells and M. hyopneumoniae, 
we confirmed that the nucleotide labels could be successfully incorporated into DNA using 
DNA polymerase by PCR amplification of template DNA. Cy3-dNTPs-containing PCR 
products were confirmed by gel electrophoresis and by measuring fluorescence using a 
fluorometer (data not shown). BrdU was also able to be incorporated into PCR products and 
was confirmed by dot blot and a subsequent ELISA (data not shown). 
EdU as a Nucleotide Label of THP-1 Cells and M. hyopneumoniae Cells 
Multiple labeling techniques for efficient nucleotide labeling in THP-1 cells were 
examined including the use of Cy3-dNTPs and the thymidine analogs BrdU and EdU. Due to 
the delocalized charge of Cy3 fluorophores, the THP-1 cell membrane was impermeable to 
the Cy3-dNTP fluorescent nucleotides. As THP-1 cells are grown in suspension, common 
techniques for labeling with Cy3-dNTPs such as scratch-loading or microinjection were not 
available. BrdU successfully labeled THP-1 cells and M. hyopneumoniae, but the harsh 
treatment of the samples in order to detect the BrdU with a fluorescently labeled antibody 
proved to be unfavorable by degrading the integrity of the METs. Since METs are quite 
fragile, the continuous washes and acid treatment made it difficult to maintain the METs in 
order to visualize and confirm that the thymidine analog BrdU was present in the METs. EdU 
was the only label tested that could work effectively for these studies.   
The detection of EdU incorporation into nucleic acids involved a reaction between the 
alkyne group on EdU and the azide group conjugated to a fluorophore in a reaction called 
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‘Click’ chemistry (65). In the presence of copper, the alkyne and azide groups undergo a 
cycloaddition reaction creating a stable triazole ring. This biorthogonal reaction is quite 
specific with little to no cross reactivity. Visualization of the labeled THP-1 cells by 
fluorescence microscopy depicted a strong presence of EdU incorporation in the nucleus of 
the THP-1 cells as seen by the Alexa555 fluorophore (Figure 1).  
 
 
Figure 1. EdU incorporation into the nucleus 
of THP-1 cells. Nucleic acid is stained with 
DAPI (blue) and the EdU is detected with an 
Alexa555 fluorophore (red). THP-1 cells were 
visualized using fluorescence confocal 
microscopy. 
 
 
 
 
The nucleotide labeling of M. hyopneumoniae cells was performed in a similar 
manner to the labeling of the THP-1 cells. Mycoplasma hyopneumoniae was incubated with 
10 µM, 1 µM, 100 nM, and 10 nM EdU for 24 h prior to being centrifuged, washed, and 
reacted with the Alexa555-azide. All concentrations of EdU were sufficient to label M. 
hyopneumoniae DNA (Figure 2). In general, the mean fluorescent intensity (MFI) of EdU 
decreased with the reduction in EdU concentrations in the incubation with M. 
hyopneumoniae, although no statistically significant difference in MFI values was noticed 
between 1 µM and 10 µM EdU (Figure 3). This is most likely due to an EdU incorporation 
threshold since it is a thymidine analog. 
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Figure 2. M. hyopneumoniae labeled with EdU at different concentrations. Fluorescence 
confocal microscopy was used to visualize M. hyopneumoniae. DAPI (blue) was used to 
stain nucleic acids. Alexa555 (red) was used to identify EdU within the M. hyopneumoniae 
cell and was visualized with a TRITC filter. Composite images show the co-localization of 
EdU and nucleic acids within the cell. Scale bar represents 10 µm. 
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Figure 3. Corrected total cellular fluorescence (CTCF) MFI values for M. hyopneumoniae 
incubated with varying concentrations of free EdU. * indicates p-value <0.001. ns indicates 
not significant. Data represents the mean MFI ± SEM with n = number of cells analyzed; 
Untreated: 437 ± 10.19, n=204; 10 nM: 482.8 ± 67.29, n=17; 100 nM: 1574 ± 332.8, n=92; 1 
µM: 2604 ± 213, n=254; 10 µM: 2428 ± 148.9, n=256. 
 
M. hyopneumoniae Nuclease Function Assays 
To validate the functionality of the membrane nuclease of M. hyopneumoniae, the 
nuclease activity assay described by Minion et al. (9) was repeated. Their experiments 
suggested that 5 mM magnesium significantly increased nuclease activity. Our nuclease 
assay verified the results reported that the addition of 5 mM was sufficient to induce nuclease 
activity (Figure 4). When M. hyopneumoniae was incubated with 5 mM magnesium, the PCR 
product was degraded (Lanes 3-4, Figure 4). Lane 5 provides evidence that no nuclease 
activity resides in the media since the PCR product was not degraded. When the experiment 
was repeated in various cell media and PBS, no inadvertent nuclease activity could be 
Un
tre
ate
d
10
nM
10
0 n
M
1 µ
M
10
 µM
0
2000
4000
6000
8000
EdU Concentration
A
le
xa
55
5 M
FI
ns
*
*
*
 33 
detected (Figure 5). Lanes 3-5 of the agarose gel indicate no degradation of the PCR product 
in any of the medium used (i.e. PBS, Friis medium, RPMI-1640 with and without 10% FBS). 
 
Figure 4. Analysis of surface nuclease 
activity in M. hyopneumoniae by agarose 
gel. Lanes: 1, NEB 2-Log DNA Ladder; 2, 
4 Kb PCR product (DNA); 3, DNA and M. 
hyopneumoniae in PBS; 4, DNA and M. 
hyopneumoniae in culture medium; 5, 
DNA in culture media alone (control for 
any nucleases in the media). Lanes 3-5 
contain 5 mM Mg2+ as a co-factor for the 
nuclease. M. hyopneumoniae was 
incubated with a PCR product in PBS and 
in Friis medium to detect nuclease activity 
of the bacterium. The membrane-
associated nucleases were stimulated with 
5 mM Mg2+. 
 
 
 
 
Figure 5. Assessing the nuclease activity in 
broth media and PBS in the absence of M. 
hyopneumoniae. Lanes: 1, NEB 2-Log DNA 
Ladder; 2, PCR product; 3, PBS; 4, M. 
hyopneumoniae Friis medium; 5, RPMI-
1640; 6, RPMI-1640 supplemented with 10% 
FBS. The nuclease assay was completed by 
adding a PCR product to various media used 
throughout the THP-1 study as well as PBS. 
The media and PCR product were incubated 
at 37°C for 30 min to allow any 
contaminating nucleases to degrade the PCR 
product. All of the lanes fail to display 
degradation of the PCR product indicating 
that none of the media and PBS contained 
significant nuclease activity. 
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Any effect that PMA, a protein kinase C (PKC) activator, would have on M. 
hyopneumoniae 232 functions, particularly on viability and nuclease function, was unknown. 
In order to determine if PMA had an effect on mycoplasma nuclease activity, the nuclease 
activity assay was repeated with the addition of 200 nM PMA. In the presence of PMA over 
a 24 h period, the PKC activator does not appear to inhibit M. hyopneumoniae nuclease 
function (Figure 6). Lanes 3-6 of Figure 6 represent four different time points of M. 
hyopneumoniae incubating with 200 nM PMA, all of which completely degrade the 2 Kb 
PCR fragment. For studies with THP-1 extracellular traps, M. hyopneumoniae was added 
directly to the RPMI-1640 media containing 200 nM PMA and METs. Performing the 
incubation in this manner reduced the amount of required washes to help maintain the 
integrity of the fragile METs.  
 
 
Figure 6. M. hyopneumoniae nuclease 
activity in the presence of 200 nM PMA. 
Lanes: 1, 1 Kb Plus DNA Ladder 
(Invitrogen); 2, 2 Kb PCR product in Friis 
media (-) control; 3, T30min+ M. 
hyopneumoniae; 4, T2h+ M. hyopneumoniae; 
5, T4h+ M. hyopneumoniae; 6, T24h+ M. 
hyopneumoniae; 7, PCR product (-) control.  
M. hyopneumoniae was incubated in the 
presence of 200 nM PMA for up to 24 h. At 
the indicated time points, a 2 Kb PCR 
product was added to the medium and 
incubated at 37°C for 30 minutes to allow for 
the degradation of the PCR product by the 
nucleases.  
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THP-1 Cells can Produce Extracellular Traps 
The conditions for MET production were determined by optimizing PMA 
concentration, FBS concentration, and the length of incubation time. THP-1 cells required 
200 nM PMA in RPMI-1640 supplemented with 1% or less FBS for MET induction while 
being incubated at 37°C with 5% CO2 for 36 h (Figure 7). Low serum concentrations were 
essential for the production of ETs since serum contains antioxidant activities. The coverslips 
were stained with DAPI to stain nucleic acid and Cell Tracker Green was utilized to identify 
THP-1 cells. DNA was observed in the extracellular space resembling extracellular traps. It 
should be noted that MET production among macrophages increased with reduced 
concentrations of FBS (data not shown). Interestingly, not every macrophage within the 
population would release METs at the same time, if at all; thus, it was not possible to 
synchronize the MET production across the entire cell layer (data not shown).  
 
 
Figure 7. THP-1 cells producing 
extracellular traps. Cell Tracker (green) 
was used to identify the THP-1 cells. DAPI 
(blue) was used to stain the nucleic acids 
that have been released upon PMA 
treatment to form METs. The dark blue 
represents the released chromosomal DNA 
(METs) and the green is the cellular 
cytoplasm.THP-1 cells and released METs 
were visualized using fluorescence 
confocal microscopy. Scale bar represents 
20 µm. 
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The production of extracellular traps from THP-1 cells was further investigated by the 
induction of METs in EdU-labeled THP-1 cells. This was necessary because the nucleotide 
label was to be used to track the transfer of nucleotides from the METs to M. hyopneumoniae 
in later experiments. EdU was chosen as a nucleotide label because of the simplicity of 
detection and the ability to visualize the label within ETs, unlike BrdU in which the DNA 
must be denatured in order to detect the presence of BrdU by antibody detection. There was a 
steric hindrance that occurred in normal DNA preventing the binding of the anti-BrdU 
antibody. THP-1 cells were incubated with 10 µM EdU for 24 h prior to washing the cells of 
excess EdU and inducing MET production with PMA. After 36 h of PMA stimulation, 
coverslips were processed for EdU detection and stained with DAPI for nucleic acids and 
examined by confocal microscopy. Imaging results displayed differentiated THP-1 cells with 
expelled ETs, dense with EdU according to fluorescence (Figure 8). The EdU appeared to be  
distributed throughout the entire MET as seen by the co-localization of the EdU label and the 
MET DNA. 
M. hyopneumoniae Can Utilize EdU Obtained From Labeled METs 
The inability of M. hyopneumoniae to synthesize purines and pyrimidines is a direct 
result of the organism’s minimal genome, consequentially forcing M. hyopneumoniae to 
obtain nucleic acid precursors from the host. To determine whether M. hyopneumoniae is 
able to utilize released nucleotides from extracellular traps via the membrane nuclease, M. 
hyopneumoniae was incubated with EdU-labeled THP-1 cells that were induced to produce 
METs. THP-1 cells were incubated with EdU for 24 h, pelleted, and the supernatant (pre-
wash solution) containing unincorporated EdU was retained prior to continuing with the 
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washes. The final wash supernatant (post-wash solution) was also retained prior to inducing 
THP-1 cells for MET production. Mycoplasma hyopneumoniae was incubated in the pre- and 
post-wash solutions to test for the presence of free EdU. After 24 h incubation, EdU is 
incorporated into M. hyopneumoniae DNA from the pre-wash (Figure 9). 
 
 
 
Figure 8. THP-1 cells producing METs containing EdU. DAPI (blue) was used to stain 
nucleic acids and an Alexa555 fluorophore (red) was used to identify the location of EdU 
within the released DNA. The purple color and white arrows indicate points of interest 
containing co-localization of DNA and the EdU nucleotide label. THP-1 cells were labeled 
with EdU by incubating the label with the monocytes for 24 h. The EdU-labeled THP-1 cells 
were then induced for the production of METs with 200 nM PMA for 36 h. The cells and 
MET structures were visualized using fluorescence confocal microscopy for the presence of 
EdU within the produced MET structures. 
 
 
This demonstrates that M. hyopneumoniae can be labeled with the same EdU used to label 
the THP-1 cells. The post-wash solution failed to label M. hyopneumoniae (Figure 9). This 
showed that any detectable EdU labeling of mycoplasma DNA must have come from the 
labeled THP-1 chromosomal DNA and not from the supernatant alone. When M. 
hyopneumoniae was incubated with EdU-labeled METs for 6 h, the EdU nucleotide could be 
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visualized co-localizing with M. hyopneumoniae DNA (Figure 10). Additionally, a lack of 
residual METs remain after incubation with M. hyopneumoniae (Figure 11). Since we 
previously tested for nuclease activity in RPMI-1640 medium, the degradation of the MET 
structures must be due to M. hyopneumoniae alone.  
 
 
Figure 9. Fluorescent staining of M. hyopneumoniae cells after 24 h incubation with pre- and 
post-wash solutions. M. hyopneumoniae was incubated with EdU-containing medium used to 
label THP-1 cells (pre-wash) and the supernatant from the final wash of THP-1 cells (post-
wash). Bacteria incubated with the pre-wash solution display vibrant fluorescence with the 
TRITC filter indicating a strong presence of the Alexa555-azide used to detect EdU within M. 
hyopneumoniae. Co-localization of Alexa555 (red) and nucleic acid (DAPI) indicated 
incorporation into the DNA. M. hyopneumoniae incubated in the post-wash solution fail to 
fluoresce under the TRITC filter meaning no detectable EdU remained in the solution 
containing the EdU-labeled THP-1 cells prior to induction with PMA. All cells were imaged 
using fluorescence confocal microscopy. Scale bar represents 10 µm.  
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Figure 10. Fluorescent imaging of M. hyopneumoniae after incubation with THP-1 cell 
METs. M. hyopneumoniae was incubated with EdU-labeled METs for 6 h to determine if it 
can utilize the nucleotides found in ETs for the construction of nucleic acids. After the 
incubation, M. hyopneumoniae was processed for fluorescence confocal microscopy using 
DAPI and an Alexa555 fluorophore to detect EdU. (a) DAPI (blue) staining nucleic acids in 
M. hyopneumoniae. (B) Detection of EdU label in M. hyopneumoniae using an Alexa555 
fluorophore (red). (C) Overlay of the images illustrating co-localization of M. 
hyopneumoniae DNA and the EdU nucleotide label depicted by the purple color. Scale bar 
represents 10 µm.  
 
 
 
. 
 
Figure 11. THP-1 METs after incubation with M. hyopneumoniae. M. hyopneumoniae was 
incubated with EdU-containing METs for 6 h. Fluorescence confocal microscopy was 
performed after the incubation to assess the condition of the METs. DAPI (blue) is staining 
nucleic acids and EdU is detected by Alexa555 fluorophore (red). (A) EdU-containing METs 
prior to incubation with M. hyopneumoniae. (B) No METs remain after incubation with M. 
hyopneumoniae; only non-MET producing EdU-labeled THP-1 cells are visible (purple). 
Scale bar represents 20 µm.  
B 
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Inhibited M. hyopneumoniae Nucleases Results in Decreased EdU Uptake and MET 
Degradation 
We predicted that the membrane nuclease of M. hyopneumoniae would be vital in the 
degradation of extracellular trap structures followed by the uptake of the liberated 
nucleotides. Since no known mutant currently exists for M. hyopneumoniae nuclease, we 
chose to chelate required Mg2+ and Ca2+ co-factors of nuclease activity (9). These divalent 
cations were chelated in the RPMI-1640 medium after the release of METs using 6 mM 
EDTA and EGTA for the complete sequestering of Mg2+ and Ca2+, respectively. Inactivating 
the enzymes by chelating magnesium and calcium ions within the RPMI-1640 medium was 
first tested using a nuclease activity assay. When 6 mM EDTA and EGTA was added to 
RPMI-1640 including 1 Kb and 1.3 Kb PCR products, no degradation of the PCR products 
could be seen with either EDTA or EGTA alone, or the addition of both solutions in the same 
reaction (Figure 12). The medium (RPMI-1640) alone, however supported nuclease activity 
(Lane 5) because it contains Ca2+ and Mg2+. 
 
 
Figure 12. Inhibition of M. hyopneumoniae 
nuclease activity by  EDTA and EGTA.  
DNA (PCR product) was incubated with M. 
hyopneumoniae in different solutions and 
then visualized on an agarose gel. Lanes: 1, 
NEB 2-Log DNA Ladder; 2, 6 mM EDTA; 
3, 6 mM EGTA; 4, 6 mM EDTA and 6 mM 
EGTA; 5, RPMI-1640; 6, PCR product 
control. 
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When M. hyopneumoniae was incubated with EdU-labeled METs and the chelating 
agents for 6 h, ETs produced by THP-1 cells remained intact on the glass coverslips 
following incubation with M. hyopneumoniae (Figure 13). Additionally, when M. 
hyopneumoniae was analyzed for the transfer of EdU from these EDTA-EGTA METs, there 
is little to no detectable EdU co-localizing with M. hyopneumoniae genomic DNA (Figure 
14). The MFI of the mycoplasmas was calculated and shows the difference in uptake of EdU 
between the EDTA/EGTA treated and untreated THP-1 cells (Figure 15). Mycoplasma 
hyopneumoniae that “fed” on EDTA/EGTA treated THP-1 METs displayed about a fifth of 
the MFI value compared to the M. hyopneumoniae that had free Mg2+ and Ca2+ cations, 
making the MFI values between the two statistically significant with a p-value of >0.001. 
These results support conclusions that the nuclease is capable and necessary for the 
degradation of extracellular traps and that the free nucleotides resulting from the 
disintegrated METs are transported into M. hyopneumoniae and used for DNA synthesis. 
During observation of EdU-labeled mycoplasmas, it appeared that the fluorescence 
intensity in mycoplasmas incubated with free EdU was not as bright as mycoplasmas “fed” 
on THP-1 cell METs. To test this, we analyzed mycoplasmas under both conditions at the 
same confocal settings (laser power, etc.). The results are shown in Figures 3 and 16. When 
M. hyopneumoniae is incubated with 1-10 µM of free EdU in solution, the mean MFI values 
are around 3,000 fluorescence AU. Comparatively, when M. hyopneumoniae procures EdU 
from METs, the mean MFI values are just below 8,000 fluorescence AU. 
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Figure 13. Fluorescent microscopy images of THP-1 METs after incubation with M. 
hyopneumoniae and EDTA and EGTA. EDTA and EGTA were added to the solution 
containing THP-1 METs prior to adding M. hyopneumoniae to chelate nuclease cofactors. 
After a 6 h incubation of M. hyopneumoniae with the treated METs, METs remain intact. 
DNA is stained with DAPI (blue) and EdU is detected with an Alexa555 fluorophore (red). 
Purple indicates the co-localization of DNA and EdU. Scale bar represents 20 µm. 
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Figure 14. Fluorescent microscopy of M. hyopneumoniae incubated with METs with 
and without EDTA and EGTA treatment. In the absence of EDTA and EGTA, EdU 
from the METs can be seen co-localizing with M. hyopneumoniae DNA (top). When 
EDTA and EGTA are added, little to no EdU can be detected in M. hyopneumoniae, 
thus demonstrating the importance of the membrane nuclease. DAPI (blue) was used 
to stain nucleic acids, and an Alexa555 fluorophore (red) was imaged with a TRITC 
filter for detection of EdU within M. hyopneumoniae DNA. Scale bars represent 10 
µm.  
 
 
 
Figure 15. Mean fluorescence 
intensity (MFI) of M. 
hyopneumoniae following interaction 
with EdU-labeled METs with and 
without treatment with EDTA and 
EGTA. * indicates a p-value <0.001. 
Data represents mean MFI ± SEM, n 
= number of cells analyzed; 
Background: 201.4 ± 1.038, n=40; 
Treated: 874.9 ± 124.5, n=50; 
Untreated: 4803 ± 595.8, n=30. 
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            D 
Figure 16. Fluorescent imaging and MFI values of M. hyopneumoniae cells after incubation with 
THP-1 cell METs. (A) DAPI (blue) staining nucleic acids in M. hyopneumoniae. (B) Detection of 
EdU label in M. hyopneumoniae using an Alexa555 fluorophore (red). (C) Overlay of the images 
illustrating co-localization of M. hyopneumoniae DNA and the EdU nucleotide label depicted by 
the magenta color. Scale bar represents 10 µm. (D) MFI values of Alexa555 fluorophore used to 
detect EdU. Abbreviations: Control, MFI value of background; IntDen, mean fluorescence 
intensity of M. hyopneumoniae that obtained EdU from METs; CTCF, corrected total cell 
fluorescence of M. hyopneumoniae that obtained EdU from METs. * indicates a p-value <0.001. 
Data represents mean MFI ± SEM, n = number of cells analyzed; Control: 179.5 ± 0.4161, n=60; 
IntDen: 7882 ± 1019, n=195; CTCF: 7311 ± 952.9, n=195. 
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CHAPTER 4. DISCUSSION 
 
This study provides evidence of the capabilities of M. hyopneumoniae to avoid killing 
by extracellular traps (ETs) by employing a membrane bound nuclease to degrade the 
chromatin structures. It also provides a possible model of purine and pyrimidine procurement 
in vivo for M. hyopneumoniae; that is from ETs. By modulating the killing nature of ETs and 
by procuring nucleic acid precursors, M. hyopneumoniae is likely to be able to grow, 
reproduce, and survive in the host by evading the immune system. 
Leukocytes are primary members of the innate immune system and are involved in 
encountering and eliminating invading pathogens. It is well established that neutrophils, a 
member of the leukocyte family, participate in phagocytosis of pathogens and degranulation 
in order to eliminate invading microorganisms, but a third mechanism, the release of ETs for 
the entrapment of pathogens, is becoming widely excepted (51). The majority of research on 
ETs has been performed in neutrophils. However, a wide variety of cells produce ETs, 
including eosinophils, mast cells, macrophage, and endothelial cells (66, 67). The induction 
of ETosis is due to stimuli such as PAMPs located on the surface of pathogens (6), and there 
is also evidence that neutrophils can sense the size of a pathogen and release NETs if the 
pathogen is too large to be phagocytized or is resistant to phagocytosis (61). In the case of M. 
pneumoniae, TLR-2 recognizes lipoproteins expressed on the cell surface resulting in the 
release of NETs (7). Although ETs eliminate the majority of pathogens, many bacteria have 
evolved resistance mechanisms including degrading the traps, inhibiting the release of the 
traps, or by altering the cell surface to avoid entrapment (68). M. hyopneumoniae, among 
other Mycoplasma spp., have exhibited cell surface nucleases (7, 9). These nucleases could 
aid Mycoplasma in avoiding elimination by ETs and provide a mechanism to acquire nucleic 
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acid precursors in vivo. In this study, we assessed the interactions between M. 
hyopneumoniae and METs and observed the ability of M. hyopneumoniae to evade 
entrapment in the METs via its nuclease and utilize the freed nucleotides for the synthesis of 
its own genetic material.  
In our preliminary experiments, we determined EdU to be the nucleotide label of 
choice after attempting to use Cy3-dNTPs and the thymidine analog BrdU. The localized 
charge on Cy3 made the synthetic dye impermeable to the THP-1 membrane (69). Other 
techniques such as scratch replication loading or microinjection of the dye directly into THP-
1 cells was not feasible since THP-1 cells are grown in suspension. Alternatively, it was 
possible to label both THP-1 cells and M. hyopneumoniae with the thymidine analog BrdU. 
Detection of BrdU requires the binding of an antibody to the analog after DNA denaturation 
to avoid steric hindrance between the antibody and the DNA. The methods of denaturation 
usually require heat, acid, or DNase treatment, all of which destroyed extracellular traps and 
produced inconsistent results. We were unable to confirm BrdU-incorporation in the METs 
making BrdU an unfavorable label. The use of EdU, however, allowed us to visualize the 
analog incorporated into the METs. Due to the cycloaddition reaction between the alkyne 
group on EdU and the fluorescent azide, no denaturation of the DNA was required. Detection 
of the label was efficient and the results were reproducible and reliable due to the 
biorthogonal nature of the reaction.  
Infection with M. hyopneumoniae is chronic, which leads us to believe that this 
microorganism has the ability to successfully evade and modulate the host immune system. 
Mycoplasma hyopneumoniae induces the loss of cilia from epithelial cells, which reduces the 
clearance of pathogens from the respiratory tract. Also, we know the lesions observed in M. 
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hyopneumoniae infections are the result of an abnormal immune response through the 
cytotoxic activities of phagocytic cells and the induction of inflammatory cytokines. A study 
by Park et al. attributed the loss of cilia on tracheal epithelial cells to the effect M. 
hyopneumoniae has through induction of intracellular Ca2+concentrations (3). An increase of 
intracellular Ca2+ release from the ER within neutrophils is the first driving step of NETosis. 
Furthermore, Debey et al. reported that intracellular calcium concentrations in neutrophils 
increase in the presence of M. hyopneumoniae and also when TLR-2 was stimulated with 
zymosan (70). These combined observations could point towards the presence of ETs at sites 
of M. hyopneumoniae infections.  
We found that M. hyopneumoniae easily degraded the exposed extracellular DNA of 
METs. These experiments were facilitated by using THP-1 monocytes as a model since the 
METs produced are structurally and compositionally similar to neutrophil ETs, and 
macrophages undergo the same type of ETosis as neutrophils when stimulated with PMA 
(71). When M. hyopneumoniae was allowed to incubate with THP-1 METs for 6 h, no 
residual METs remained even though plenty of METs were produced as seen on the 
coverslips without M. hyopneumoniae incubation (data not shown). The incubation time of 6 
h was determined based on the M. hyopneumoniae in vitro replication time (72) and allowed 
for maximal efficiency of EdU labeling due to the lack of multiple rounds of M. 
hyopneumoniae replication.  
Mycoplasma hyopneumoniae is reliant on its host for purines and pyrimidines since it 
lacks the biosynthetic pathways to provide the nucleic acid precursors among other 
macromolecule building blocks. In this study, we found that M. hyopneumoniae transported 
the released MET nucleotides into the bacterial cell and utilized them for the construction of 
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its own nucleic acids. Interestingly, higher MFI values were recorded in M. hyopneumoniae 
that were allowed to “fed” upon the METs than the MFI values seen in experiments where 
the bacterium was incubated with soluble EdU (Figures 3 and 16). These two experiments 
were analyzed under the same confocal conditions with differences in incubation times; M. 
hyopneumoniae was incubated with METs for 6 h or with free EdU for 24 h. This apparent 
difference in uptake efficiencies suggests that the nuclease responsible for disassembly of 
METs is coupled with a transport system allowing for more efficient uptake of nucleotides 
released from cellular DNA. Like other mycoplasmas, M. hyopneumoniae contains several 
nucleases, all of which are found in intact cells, that could function in degrading NETs (9).	  
One of these nucleases is mhp379, a calcium-dependent membrane exonuclease (8). Just 
upstream of mhp379 in the 232 genome (24) are two lipoproteins, and downstream are potA, 
an ABC transporter, and two sn-glycerol-3-phosphate transport system permeases, upgA and 
ugpE, that could function as a nucleotide transport system (8). In keeping with previous 
studies, the degradation of METs and subsequent uptake of released EdU from labeled METs 
required calcium and magnesium. In the absence of a specific nuclease inhibitor, we chose to 
inhibit the M. hyopneumoniae nuclease with EDTA and EGTA. We show that nucleolytic 
activity was absent in such treated cells (Figure 6). These cells when incubated with EdU-
labeled METs, failed to degrade the METs (Figure 7) and take up EdU during the incubation 
period (Figure 8), showing a direct relationship of MET degradation and EdU uptake by the 
mycoplasma.  
We did, however, witness an uneven distribution of EdU throughout the M. 
hyopneumoniae population exposed to METs as was illustrated by the large standard error 
values of the MFI values (Figure 3). Only those mycoplasmas with detectable label were 
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considered for this analysis, and this variation could be explained by a number of variables. 
First, the only source of EdU in the reaction should then be the METs themselves. 
Conceivably, the 6 h incubation of mycoplasmas with THP-1 cells could result in some cell 
death and release of free EdU, but Figure 11 clearly shows that many THP-1 cells remain 
intact throughout the incubation and the mycoplasmas have minimal effect on their viability. 
Any released free EdU would add little to the overall concentration of EdU in the 
supernatant. Next, the direct interaction of the mycoplasma with the MET should be 
considered as transient. Mycoplasma hyopneumoniae is not known to bind to DNA. Also, not 
all mycoplasmas could be expected to encounter a MET during the incubation period. In fact, 
there were significant numbers of unlabeled mycoplasmas (~20%) observed following 
incubation with the METs (data not shown). Thus, there would be different populations of 
mycoplasmas in the incubation mixture, those that interact with METs extensively, those that 
interact intermittently and those that do not interact. When one considers that not all MET 
DNA is labeled equally, the release of EdU is going to be non-uniform. There is one more 
possible source of EdU in the cell-mycoplasma mixture; during the nuclease degradation of 
the MET, it is expected that some EdU could be released into the supernatant and be 
available for transport by the mycoplasma. In this case, one would expect the effective 
concentration of EdU in the supernatant to be low with a concomitant low or undetectable 
signal in the mycoplasma. Finally, EdU is a thymidine analog and has the ability to replace 
thymidine but does not outcompete it for incorporation into nucleic acids. The variability of 
MFI values between M. hyopneumoniae could also be due at least partially to variable 
replacement of thymidine with EdU.  
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Additionally, we found that the degradation of the METs and transfer of EdU was 
significantly reduced when M. hyopneumoniae membrane nucleases were deprived of 
magnesium and calcium cations. This supports our hypothesis that M. hyopneumoniae 
nucleases are responsible for the degradation of ETs. Although we continued to see the EdU 
in M. hyopneumoniae after treatment with EDTA and EGTA, the mean fluorescence intensity 
between the EDTA/EGTA-treated group and the untreated group were statistically significant 
in that the MFI of the treated group has a decreased presence of EdU. Residual magnesium or 
calcium in the media that was not chelated by EDTA and EGTA could contribute to the 
presence of EdU in the treated group. Also, ETs are incredibly fragile so it is possible to say 
M. hyopneumoniae was able to transport nucleotides that were already freed from the METs 
upon addition of the culture to the coverslips or that were released in the handling of the 
plate.  
The results of this study provide insight into possible virulence mechanisms of M. 
hyopneumoniae and the bacterium’s procurement of nucleic acid precursors. Although we do 
not yet have a complete picture of how M. hyopneumoniae perpetually causes disease in 
swine, we do have one more piece to the puzzle. This puzzle piece will hopefully aid us in 
developing potential preventative therapeutic agents for the control and prevention of M. 
hyopneumoniae infections throughout the worldwide swine industry. 
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